Solidarity Trial: Hydroxychloroquine, Remdesivir etc.
Will remdesivir soon join the hydroxychloroquine and lopinavir graveyard? Interim results from the Solidarity Therapeutics Trial, coordinated by the World Health Organization, indicate that remdesivir, hydroxychloroquine, lopinavir and interferon regimens appear to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. This paper is currently being peer-reviewed.
WHO Solidarity Trial Consortium, Pan, H, Peto R, et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. medRxiv 2020, posted 15 October. Full-text: https://doi.org/10.1101/2020.10.15.20209817
Figure 2. Effect of remdesivir and hydroxychloroquine on 28-day mortality. Copyright: WHO. Reproduced with permission.
See also the press articles in
English: Boseley S. Remdesivir has very little effect on Covid-19 mortality, WHO finds. The Guardian 2020, published 16 October. Full-text: https://www.theguardian.com/world/2020/oct/16/remdesivir-has-very-little-effect-on-covid-19-mortality-who-finds-trial-drug-coronavirus
Results from gold-standard trial described as sobering, as drug found not to improve survival rates
Spanish: Domínguez N. La OMS confirma que ninguno de los fármacos contra la covid que estaba probando salva vidas. El País 2020, published 16 October. Full-text: https://elpais.com/ciencia/2020-10-16/la-oms-confirma-que-ninguno-de-los-farmacos-contra-la-covid-que-estaba-probando-salva-vidas.html
Los datos del ensayo Solidarity confirman que ni la cloroquina ni el remdesivir ni otros dos tratamientos reducen la mortalidad.